From: HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus
Baseline characteristics | Overall n=1,588 | DM n=153 | No DM n=1,435 | p value |
---|---|---|---|---|
Age at first assessment, mean (SD) | 51.0 (13.6) | 58.1 (9.6) | 50.3 (13.5) | <0.001 |
Age category, n (%) | ||||
 ≤29 | 134 (8.4) | --- | 134 (9.3) | <0.001 |
 30-39 | 185 (11.7) | 4 (2.6) | 181 (12.6) | |
 40-49 | 291 (18.3) | 24 (15.7) | 267 (18.6) | |
 50-59 | 532 (33.5) | 51 (33.3) | 481 (33.5) | |
 60-69 | 365 (23.0) | 59 (38.6) | 306 (21.3) | |
 ≥70 | 81 (5.1) | 15 (9.8) | 66 (4.6) | |
Male sex, n (%) | 1,010 (63.6) | 108 (70.6) | 902 (62.9) | 0.059 |
Race, n (%)a | ||||
 Caucasian | 1,064 (83.3) | 106 (79.1) | 958 (83.8) | 0.205 |
 Black | 79 (6.2) | 13 (9.8) | 66 (5.8) | |
 Asian | 46 (3.6) | 3 (2.2) | 43 (3.8) | |
 Indigenous | 69 (5.4) | 9 (6.7) | 60 (5.2) | |
 Hispanic | 4 (0.3) | --- | 4 (0.4) | |
 Other | 15 (1.2) | 3 (2.2) | 12 (1.0) | |
HCV RNA (IU/mL), mean (SD) | 3.9x106 (13.3x106) | 3.3 x106 (6.5x106) | 3.9 x106 (13.9x106) | 0.384 |
Genotype, n (%)a | ||||
 G1a | 693 (51.4) | 63 (46.1) | 630 (52.0) | 0.010 |
 G1b | 113 (8.4) | 15 (10.9) | 98 (8.1) | |
 G1 (other subtypes) | 46 (3.4) | 2 (1.5) | 44 (3.6) | |
 G2 | 99 (7.3) | 15 (10.9) | 84 (6.9) | |
 G3 | 293 (21.7) | 26 (19.0) | 267 (22.0) | |
 G4 | 52 (3.8) | 15 (10.9) | 37 (3.0) | |
 G5 | 3 (0.2) | 1 (0.7) | 2 (0.2) | |
 G6 | 8 (0.6) | --- | 8 (0.7) | |
 G mixed | 42 (3.1) | --- | 42 (3.5) | |
Liver stiffness (kPa), mean (SD) | 11.2 (11.8) | 18.3 (15.6) | 11.2 (11.1) | <0.001 |
CAP score (dB/mL), mean (SD) | 246 (61) | 262 (71) | 244 (60) | 0.001 |
Fibrosis Stage, n (%)a | ||||
 F0-F1 | 766 (52.1) | 35 (24.6) | 731 (55.0) | <0.001 |
 F2 | 197 (13.4) | 16 (11.3) | 181 (13.6) | |
 F3 | 172 (11.7) | 25 (17.6) | 147 (11.1) | |
 F4b | 335 (22.8) | 66 (46.5) | 269 (20.3) | |
Year of assessment, n (%) | ||||
 2014 | 239 (15.0) | 24 (15.7) | 215 (15.0) | 0.552 |
 2015 | 292 (18.4) | 23 (15.0) | 269 (18.7) | |
 2016 | 289 (18.2) | 29 (18.9) | 260 (18.1) | |
 2017 | 244 (15.4) | 37 (24.2) | 207 (14.4) | |
 2018 | 243 (15.3) | 21 (13.7) | 222 (15.5) | |
 2019 | 230 (14.5) | 14 (9.2) | 216 (15.1) | |
 2020 | 51 (3.2) | 5 (3.3) | 46 (3.2) | |
Baseline Laboratory Measures | ||||
 ALT (IU/L), mean (SD) | 92 (104.2) | 92 (101) | 91 (105) | 0.922 |
 AST (IU/L), mean (SD) | 66 (66.9) | 67 (72) | 66 (66) | 0.859 |
 Bilirubin (mmol/L), mean (SD) | 11 (10.0) | 13 (16.5) | 11 (8.6) | 0.157 |
 Hemoglobin (g/L), mean (SD) | 140 (20) | 137 (19) | 140 (20) | 0.031 |
 Platelets (109/L), mean (SD) | 208 (81) | 197 (88) | 209 (80) | 0.073 |
 Creatinine (umol/L), mean (SD) | 77 (71) | 95 (98) | 75 (66) | 0.016 |
Comorbidities | ||||
 HIV co-infection, n (%) | 61 (3.8) | 6 (3.9) | 55 (3.8) | 0.957 |
 Psychiatric condition, n (%) | 751 (47.3) | 77 (50.3) | 674 (47.0) | 0.429 |
 Hepatocellular carcinoma, n (%)a | 37 (2.3) | 9 (5.9) | 28 (1.8) | 0.001 |
 Chronic renal disease, n (%)a | 34 (2.3) | 20 (13.1) | 14 (1.0) | <0.001 |
Socioeconomic determinants of health | ||||
 Immigrant, n (%) | 269 (16.9) | 44 (28.8) | 225 (16.7) | <0.001 |
 Currently employed, n (%) | 305 (28.6) | 35 (26.5) | 270 (28.9) | 0.564 |
 Alcohol use history, n (%) | 733 (55.7) | 72 (47.1) | 661 (56.9) | 0.013 |
 Incarceration history, n (%)a | 634 (49.0) | 58 (38.2) | 576 (50.4) | 0.006 |
 IDU history, n (%)a | 813 (62.4) | 83 (54.6) | 730 (63.5) | 0.047 |
 Recreational drug use history, n (%)a | 749 (58.2) | 69 (45.4) | 680 (59.9) | 0.007 |
HCV treatment outcomes | ||||
 DAA therapy initiated, n (%) | ||||
  Yes | 1,072 (67.5) | 133 (86.9) | 939 (65.4) | <0.001 |
  No | 516 (32.5) | 20 (13.1) | 496 (34.6) | |
Crude SVR rate, n (%) | 831/995 (83.6) | 118/131 (90.1) | 713/864 (86.8) | 0.032 |
Post treatment testing SVR rate, n (%) | 831/846 (98.2) | 118/122 (96.7) | 713/724 (98.5) | 0.173 |
 Newly diagnosed hepatocellular carcinoma post treatment, n (%) | ||||
  12 months post treatment | 3 (0.3) | 1 (0.8) | 2 (0.2) | --- |
  24 months post treatment | 8 (0.8) | 3 (2.3) | 5 (0.6) | --- |